Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to investigate the safety and the recommended dose for later use of an oncolytic adenovirus CGTG-102 in combination with low-dose oral cyclophosphamide in the treatment of advanced cancers.


Clinical Trial Description

CGTG-102 is an adenovirus that has been armed with granulocyte-macrophage colony stimulating factor (GMCSF), a potent stimulator of immunological cells.

With regard to oncolytic viruses, replication in normal cells does not take place, and therefore viruses such as CGTG-102 are not known to cause any disease. Further, to date there has been no incidence of passing the virus on to other humans from patients. Since the virus requires tumor cells to multiply, such events are unlikely.

To this day more than 100 patients have been treated with CGTG-102. This clinical trial will take place over approximately 6 months. The study includes 12 visits to the hospital, 1 screening visit, 9 injection visits including overnight stay at the hospital(performed on trial days 1, 4, 8, 15, 29, 57, 85, 113 and 141), 1 end of treatment visit (day 169) and 1 end of study visit (day 190). Oral treatment with cyclophosphamide (1 pill per day) will start on the day after the first injection and last until visit day 169. ;


Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01598129
Study type Interventional
Source Targovax ASA
Contact
Status Completed
Phase Phase 1
Start date April 2012
Completion date October 2013

See also
  Status Clinical Trial Phase
Completed NCT01721148 - A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours Phase 1
Completed NCT00551096 - Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors Phase 1
Completed NCT01023737 - Hydroxychloroquine + Vorinostat in Advanced Solid Tumors Phase 1
Completed NCT01435096 - BN80927 in Patients With Advanced Malignant Solid Tumors Phase 1
Completed NCT01951846 - To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours Phase 1
Completed NCT01325558 - A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors Phase 1
Completed NCT01554371 - Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies Phase 1/Phase 2
Recruiting NCT01309490 - Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients Phase 1/Phase 2
Recruiting NCT01286896 - Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors Phase 1
Completed NCT00635791 - Phase I Study of Vorinostat and Sorafenib in Advanced Cancer Phase 1
Completed NCT01376505 - Vaccine Therapy in Treating Patients With Metastatic Solid Tumors Phase 1
Completed NCT00388427 - Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies Phase 1
Completed NCT01611857 - Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach Phase 1/Phase 2
Completed NCT02853903 - Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors Phase 2
Completed NCT02843204 - Combination of Anti-PD-1 and NK Immunotherapy for Recurrent Solid Tumors Phase 1/Phase 2
Completed NCT01618136 - An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Terminated NCT00801151 - Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer Phase 1
Completed NCT02786628 - Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation
Completed NCT01184807 - Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors Phase 1
Completed NCT00969410 - A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases Phase 1